JP2019531705A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531705A5 JP2019531705A5 JP2019505188A JP2019505188A JP2019531705A5 JP 2019531705 A5 JP2019531705 A5 JP 2019531705A5 JP 2019505188 A JP2019505188 A JP 2019505188A JP 2019505188 A JP2019505188 A JP 2019505188A JP 2019531705 A5 JP2019531705 A5 JP 2019531705A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- less
- mutation
- compared
- mutations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 154
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 154
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 154
- 230000035772 mutation Effects 0.000 claims description 87
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 21
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 19
- 238000003556 assay Methods 0.000 claims description 12
- 238000001727 in vivo Methods 0.000 claims description 11
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 10
- 238000000423 cell based assay Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 8
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 8
- 239000012636 effector Substances 0.000 claims description 8
- 230000006870 function Effects 0.000 claims description 8
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 claims description 7
- 230000001419 dependent effect Effects 0.000 claims description 7
- 102100023431 E3 ubiquitin-protein ligase TRIM21 Human genes 0.000 claims description 6
- 101000685877 Homo sapiens E3 ubiquitin-protein ligase TRIM21 Proteins 0.000 claims description 6
- 108010073807 IgG Receptors Proteins 0.000 claims description 6
- 102000009490 IgG Receptors Human genes 0.000 claims description 6
- 230000008827 biological function Effects 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 239000001393 triammonium citrate Substances 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 5
- 238000002965 ELISA Methods 0.000 claims description 4
- 108010021468 Fc gamma receptor IIA Proteins 0.000 claims description 4
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims description 4
- 206010057249 Phagocytosis Diseases 0.000 claims description 4
- 239000001825 Polyoxyethene (8) stearate Substances 0.000 claims description 4
- 238000010494 dissociation reaction Methods 0.000 claims description 4
- 230000005593 dissociations Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 230000008782 phagocytosis Effects 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 3
- 238000006386 neutralization reaction Methods 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 238000004220 aggregation Methods 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 238000010171 animal model Methods 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 230000009286 beneficial effect Effects 0.000 claims description 2
- 230000001447 compensatory effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 108010068617 neonatal Fc receptor Proteins 0.000 claims description 2
- 230000031998 transcytosis Effects 0.000 claims description 2
- 150000001413 amino acids Chemical group 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022096036A JP2022120132A (ja) | 2016-08-02 | 2022-06-14 | 操作されたポリペプチドおよびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662370201P | 2016-08-02 | 2016-08-02 | |
| US62/370,201 | 2016-08-02 | ||
| US201762485671P | 2017-04-14 | 2017-04-14 | |
| US62/485,671 | 2017-04-14 | ||
| PCT/US2017/045126 WO2018052556A1 (en) | 2016-08-02 | 2017-08-02 | Engineered polypeptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096036A Division JP2022120132A (ja) | 2016-08-02 | 2022-06-14 | 操作されたポリペプチドおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531705A JP2019531705A (ja) | 2019-11-07 |
| JP2019531705A5 true JP2019531705A5 (cg-RX-API-DMAC10.html) | 2020-09-10 |
| JP7464389B2 JP7464389B2 (ja) | 2024-04-09 |
Family
ID=59656189
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505188A Active JP7464389B2 (ja) | 2016-08-02 | 2017-08-02 | 操作されたポリペプチドおよびその使用 |
| JP2022096036A Withdrawn JP2022120132A (ja) | 2016-08-02 | 2022-06-14 | 操作されたポリペプチドおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096036A Withdrawn JP2022120132A (ja) | 2016-08-02 | 2022-06-14 | 操作されたポリペプチドおよびその使用 |
Country Status (22)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012040623A2 (en) | 2010-09-24 | 2012-03-29 | The Brigham And Women's Hospital, Inc. | Nanostructured gels capable of controlled release of encapsulated agents |
| CA3032820A1 (en) | 2016-08-02 | 2018-03-22 | Visterra, Inc. | Engineered polypeptides and uses thereof |
| EP3497120A1 (en) | 2016-08-12 | 2019-06-19 | Janssen Biotech, Inc. | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions |
| CA3033665A1 (en) * | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them |
| WO2018144991A1 (en) | 2017-02-03 | 2018-08-09 | The Brigham And Women's Hospital, Inc. | Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof |
| MA50102A (fr) * | 2017-11-14 | 2020-07-15 | Univ Virginia Patent Foundation | Compositions et méthodes de fabrication et d'utilisation d'anticorps bispécifiques |
| BR112020015006A2 (pt) * | 2018-01-26 | 2020-12-29 | Genzyme Corporation | Variantes de fc com ligação realçada ao fcrn e meia-vida prolongada |
| US20210046154A1 (en) * | 2018-03-05 | 2021-02-18 | Oncoimmune, Inc | Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids) |
| US20190307885A1 (en) | 2018-04-04 | 2019-10-10 | Alivio Therapeutics, Inc. | Self-assembled gels for controlled delivery of biologics and methods of making thereof |
| EP3805400A4 (en) * | 2018-06-04 | 2022-06-29 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule showing changed half-life in cytoplasm |
| US20210317479A1 (en) | 2018-09-06 | 2021-10-14 | The Broad Institute, Inc. | Nucleic acid assemblies for use in targeted delivery |
| BR112021008486A2 (pt) * | 2018-11-01 | 2021-10-26 | Shandong New Time Pharmaceutical Co., Ltd | Anticorpo biespecífico e seu uso |
| US12655227B2 (en) * | 2018-11-22 | 2026-06-16 | Agency For Science, Technology And Research | Modified Fc region |
| EP3902836B1 (en) | 2018-12-18 | 2026-03-25 | Boehringer Ingelheim IO Canada Inc. | Flt3 agonist antibodies and uses thereof |
| CN113227131B (zh) * | 2018-12-20 | 2025-03-04 | 豪夫迈·罗氏有限公司 | 经修饰的抗体Fc及其使用方法 |
| JP7607289B2 (ja) | 2019-05-23 | 2024-12-27 | シァメン・ユニヴァーシティ | 新規の抗ｂ型肝炎ウイルス抗体及びその使用 |
| BR112021025421A2 (pt) | 2019-06-17 | 2022-02-01 | Visterra Inc | Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos |
| CN114466663B (zh) | 2019-07-25 | 2026-01-02 | 建新公司 | 以FcRn拮抗剂治疗抗体介导的障碍的方法 |
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| US20220288202A1 (en) * | 2019-09-04 | 2022-09-15 | Cedars-Sinai Medical Center | Use of Calcineurin Inhibitor Free CTLA4-IG + Anti-IL6/IL6R For Long Term Immunosuppression in Solid Organ Transplant Recipients |
| EP3819312A1 (en) * | 2019-11-10 | 2021-05-12 | Amgen, Inc | Dosing regimen for anti-dll3 agents |
| MX2022007207A (es) | 2019-12-11 | 2022-07-12 | Visterra Inc | Composiciones y metodos para tratar y prevenir la influenza. |
| TWI869528B (zh) * | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| CN111254207A (zh) * | 2020-01-22 | 2020-06-09 | 郑州大学第一附属医院 | 用于区别自身免疫性肝炎和健康人群的肠道微生物标志物及其应用 |
| KR20230042273A (ko) | 2020-06-24 | 2023-03-28 | 비스테라, 인크. | April에 대한 항체 분자 및 그의 용도 |
| CA3203977A1 (en) | 2020-12-04 | 2022-06-09 | Visterra, Inc. | Methods of using interleukin-2 agents |
| US11912781B2 (en) | 2021-01-13 | 2024-02-27 | Visterra, Inc. | Humanized complement 5A receptor 1 antibodies and methods of use thereof |
| WO2022159590A1 (en) | 2021-01-20 | 2022-07-28 | Visterra, Inc. | Interleukin-2 mutants and uses thereof |
| CA3209059A1 (en) * | 2021-02-25 | 2022-09-01 | Leslie W. Tari | Variant fc domains and uses thereof |
| TW202246339A (zh) * | 2021-03-03 | 2022-12-01 | 愛爾蘭商赫萊森治療愛爾蘭公司 | 治療甲狀腺眼疾的方法 |
| US20230348614A1 (en) | 2021-11-24 | 2023-11-02 | Visterra, Inc. | Engineered antibody molecules to cd138 and uses thereof |
| TW202333772A (zh) | 2021-12-01 | 2023-09-01 | 美商威特拉公司 | 使用介白素-2藥劑之方法 |
| CA3243493A1 (en) | 2022-02-11 | 2023-08-17 | Visterra, Inc. | INTERLEUKIN-2 MUTEINS FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
| AU2023262513A1 (en) | 2022-04-25 | 2024-12-05 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| CN115028738B (zh) * | 2022-06-14 | 2025-05-16 | 天津医科大学 | 一种Fc融合蛋白双重靶向降解剂及应用 |
| WO2024027793A1 (en) * | 2022-08-05 | 2024-02-08 | I-Mab Biopharma (Hangzhou) Co., Ltd. | Bispecific antibodies targeting ifnar1 and blys |
| US20260167741A1 (en) * | 2022-10-18 | 2026-06-18 | Crosspoint Therapeutics Inc. | Human antibody fc domain variant and use thereof |
| US20240150447A1 (en) * | 2022-11-04 | 2024-05-09 | Cephalon, LLC | Compositions and methods for increasing transport into the brain |
| CN120752260A (zh) * | 2023-03-06 | 2025-10-03 | 拜奥卡德联合股份公司 | 包含人类CD1b (分化簇1)蛋白的异二聚体的抗体样分子 |
| WO2024211779A1 (en) * | 2023-04-05 | 2024-10-10 | The Regents Of The University Of California | Affinity peptides for diagnosis and treatment of viral infections |
| CN117925664B (zh) * | 2023-11-29 | 2025-01-21 | 上海科锐克医药科技有限公司 | 用于递送人vegf受体融合蛋白的基因递送载体及其应用 |
| CN117467025B (zh) * | 2023-12-28 | 2024-04-16 | 上海鼎新基因科技有限公司 | 一种抗vegf和补体双功能融合蛋白及其应用 |
| US20260028384A1 (en) | 2024-04-17 | 2026-01-29 | Visterra, Inc. | Use of il-2 variant for treating kidney transplant rejection |
| WO2026039779A1 (en) | 2024-08-15 | 2026-02-19 | Yale University | Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding |
| US20260109746A1 (en) | 2024-10-22 | 2026-04-23 | Gilead Sciences, Inc. | Cd4-targeted il-15 molecules and methods of use |
| WO2026154422A1 (en) | 2025-01-17 | 2026-07-23 | Otsuka Pharmaceutical Company, Ltd. | Il-2-fc fusion protein for use in treating autoimmune diseases |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5843708A (en) | 1988-01-05 | 1998-12-01 | Ciba-Geigy Corporation | Chimeric antibodies |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| CA2090473A1 (en) | 1990-08-29 | 1992-03-01 | Robert M. Kay | Homologous recombinatin in mammalian cells |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| WO2004004662A2 (en) | 2002-07-09 | 2004-01-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| AU2012203476A1 (en) | 2003-11-12 | 2012-07-05 | Biogen Idec Ma Inc. | Neonatal Fc Receptor (FcRn)-Binding Polypeptide Variants, Dimeric Fc Binding Proteins and Methods Related Thereto |
| JP4762156B2 (ja) | 2004-01-12 | 2011-08-31 | アプライド モレキュラー エボリューション，インコーポレイテッド | Ｆｃ領域変異体 |
| BRPI0514068B8 (pt) | 2004-08-04 | 2021-05-25 | Applied Molecular Evolution Inc | anticorpo anti-cd20, e, composição farmacêutica |
| CA2577133A1 (en) * | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8546543B2 (en) * | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| CA2595169A1 (en) * | 2005-01-12 | 2006-07-20 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
| US20110123440A1 (en) | 2005-03-29 | 2011-05-26 | Genevieve Hansen | Altered Antibody FC Regions and Uses Thereof |
| WO2008030564A2 (en) | 2006-09-08 | 2008-03-13 | Verenium Corporation | Aglycosylated antibodies and methods of making and using those antibodies |
| US20100297103A1 (en) | 2006-09-14 | 2010-11-25 | Medical & Biological Laboratories Co., Ltd. | Antibody having enhanced adcc activity and method for production thereof |
| WO2008114011A2 (en) * | 2007-03-19 | 2008-09-25 | Medimmune Limited | Fc polypeptide variants obtained by ribosome display methodology |
| KR101616758B1 (ko) | 2007-12-26 | 2016-04-29 | 젠코어 인코포레이티드 | ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체 |
| AU2009303526B2 (en) * | 2008-10-14 | 2015-01-15 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| US8775090B2 (en) * | 2008-12-12 | 2014-07-08 | Medimmune, Llc | Crystals and structure of a human IgG Fc variant with enhanced FcRn binding |
| JP2012515556A (ja) | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法 |
| AU2015200990B2 (en) | 2009-03-20 | 2016-07-21 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Optimized Fc variants |
| EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| BRPI1015234A2 (en) | 2009-06-22 | 2018-02-20 | Medimmune Llc | fc regions designed for site specific conjugation. |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
| WO2011057198A1 (en) | 2009-11-09 | 2011-05-12 | Carson Cantwell G | Vaccine testing system |
| WO2011119484A1 (en) | 2010-03-23 | 2011-09-29 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| US20170039314A1 (en) | 2010-03-23 | 2017-02-09 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| WO2012032080A1 (en) * | 2010-09-07 | 2012-03-15 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H | Stabilised human fc |
| TWI654203B (zh) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | 具有鈣依存性的抗原結合能力之抗體 |
| AU2011349049B2 (en) | 2010-12-22 | 2016-08-11 | Teva Pharmaceuticals Australia Pty Ltd | Modified antibody with improved half-life |
| CA2826467C (en) | 2011-02-07 | 2019-11-12 | Research Development Foundation | Engineered immunoglobulin fc polypeptides |
| SG10201609665PA (en) | 2011-02-25 | 2017-01-27 | Chugai Pharmaceutical Co Ltd | FcɣRIIb-SPECIFIC Fc ANTIBODY |
| WO2012132067A1 (ja) | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| MX2013011366A (es) | 2011-03-30 | 2014-05-12 | Chugai Pharmaceutical Co Ltd | Retencion de las moleculas de union al antigeno en el plasma sanguineo y metodo para modificar la inmunogenicidad. |
| EP2698431B1 (en) | 2011-03-30 | 2020-09-09 | Chugai Seiyaku Kabushiki Kaisha | Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity |
| WO2013012733A1 (en) | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
| GB201112429D0 (en) | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| KR102366029B1 (ko) | 2011-09-30 | 2022-02-23 | 추가이 세이야쿠 가부시키가이샤 | 표적 항원에 대한 면역응답을 유도하는 항원 결합 분자 |
| KR20250078601A (ko) | 2011-09-30 | 2025-06-02 | 추가이 세이야쿠 가부시키가이샤 | 항원의 소실을 촉진시키는 항원 결합 분자 |
| TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| KR20210074395A (ko) | 2011-11-30 | 2021-06-21 | 추가이 세이야쿠 가부시키가이샤 | 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약 |
| WO2013096221A1 (en) * | 2011-12-21 | 2013-06-27 | Amgen Inc. | Variant fc-polypeptides with enhanced binding to the neonatal fc receptor |
| EP3539982B1 (en) | 2011-12-23 | 2025-02-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| EP4624490A3 (en) | 2012-02-09 | 2025-11-05 | Chugai Seiyaku Kabushiki Kaisha | Modified fc region of antibody |
| BR112014019741A2 (pt) | 2012-02-11 | 2020-12-22 | Genentech, Inc | Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado |
| CA2865158C (en) | 2012-02-24 | 2022-11-01 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib |
| CA2871934C (en) | 2012-04-30 | 2023-06-13 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| WO2013180200A1 (ja) | 2012-05-30 | 2013-12-05 | 中外製薬株式会社 | 標的組織特異的抗原結合分子 |
| JPWO2013180201A1 (ja) | 2012-05-30 | 2016-01-21 | 中外製薬株式会社 | 会合化した抗原を消失させる抗原結合分子 |
| WO2014006217A1 (en) | 2012-07-06 | 2014-01-09 | Genmab B.V. | Dimeric protein with triple mutations |
| JP6280300B2 (ja) | 2012-08-24 | 2018-02-14 | 中外製薬株式会社 | 脳疾患治療剤 |
| US20140294812A1 (en) | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| CA2904806C (en) | 2013-04-29 | 2021-11-23 | F. Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
| JP6832709B2 (ja) * | 2014-05-16 | 2021-02-24 | メディミューン，エルエルシー | 新生児Ｆｃ受容体結合が改変されて治療および診断特性が強化された分子 |
| US20170211876A1 (en) * | 2014-06-12 | 2017-07-27 | Hoffmann-La Roche Inc. | Method for selecting antibodies with modified fcrn interaction |
| FR3024453B1 (fr) | 2014-08-01 | 2018-06-29 | Lab Francais Du Fractionnement | Procede de production de variants ayant un fc presentant une sialylation amelioree |
| PT3215528T (pt) | 2014-11-06 | 2019-10-11 | Hoffmann La Roche | Variantes da região fc com ligação modificada ao fcrn e métodos de utilização |
| MX2017012805A (es) * | 2015-04-07 | 2018-04-11 | Genentech Inc | Complejo de unión a antígenos con actividad agonista y métodos de uso. |
| FR3035879B1 (fr) | 2015-05-07 | 2025-02-28 | Lab Francais Du Fractionnement | Mutants fc a activite fonctionnelle modifiee |
| US12391759B2 (en) * | 2016-03-02 | 2025-08-19 | Momenta Pharmaceuticals, Inc. | Methods related to engineered Fc constructs |
| CN109071631B (zh) | 2016-03-14 | 2023-07-14 | 奥斯陆大学 | 具有改变的FcRn结合的工程化免疫球蛋白 |
| WO2017181098A2 (en) | 2016-04-15 | 2017-10-19 | Visterra, Inc. | Antibody molecules to zika virus and uses thereof |
| CA3032820A1 (en) | 2016-08-02 | 2018-03-22 | Visterra, Inc. | Engineered polypeptides and uses thereof |
| EP3456738B1 (en) | 2017-09-19 | 2024-07-17 | Tillotts Pharma Ag | Antibody variants |
-
2017
- 2017-08-02 CA CA3032820A patent/CA3032820A1/en active Pending
- 2017-08-02 PT PT177545357T patent/PT3494134T/pt unknown
- 2017-08-02 MX MX2019001458A patent/MX2019001458A/es unknown
- 2017-08-02 LT LTEPPCT/US2017/045126T patent/LT3494134T/lt unknown
- 2017-08-02 IL IL315729A patent/IL315729A/en unknown
- 2017-08-02 JP JP2019505188A patent/JP7464389B2/ja active Active
- 2017-08-02 AU AU2017325654A patent/AU2017325654B2/en active Active
- 2017-08-02 DK DK17754535.7T patent/DK3494134T3/da active
- 2017-08-02 CN CN202410254572.6A patent/CN118085091A/zh active Pending
- 2017-08-02 KR KR1020257006561A patent/KR20250036943A/ko active Pending
- 2017-08-02 SG SG11201900616UA patent/SG11201900616UA/en unknown
- 2017-08-02 SI SI201731655T patent/SI3494134T1/sl unknown
- 2017-08-02 US US15/667,309 patent/US11858980B2/en active Active
- 2017-08-02 IL IL264590A patent/IL264590B2/en unknown
- 2017-08-02 FI FIEP17754535.7T patent/FI3494134T3/fi active
- 2017-08-02 PL PL17754535.7T patent/PL3494134T3/pl unknown
- 2017-08-02 CN CN201780059776.2A patent/CN110072887A/zh active Pending
- 2017-08-02 CN CN202410254540.6A patent/CN118388638A/zh active Pending
- 2017-08-02 WO PCT/US2017/045126 patent/WO2018052556A1/en not_active Ceased
- 2017-08-02 ES ES17754535T patent/ES3062797T3/es active Active
- 2017-08-02 KR KR1020197006298A patent/KR102777127B1/ko active Active
- 2017-08-02 HR HRP20260151TT patent/HRP20260151T1/hr unknown
- 2017-08-02 BR BR112019001989-8A patent/BR112019001989A2/pt unknown
- 2017-08-02 EP EP17754535.7A patent/EP3494134B1/en active Active
-
2019
- 2019-01-30 CO CONC2019/0000931A patent/CO2019000931A2/es unknown
- 2019-01-31 CL CL2019000261A patent/CL2019000261A1/es unknown
-
2020
- 2020-04-10 US US16/845,894 patent/US20200277358A1/en not_active Abandoned
-
2022
- 2022-01-06 CL CL2022000036A patent/CL2022000036A1/es unknown
- 2022-06-14 JP JP2022096036A patent/JP2022120132A/ja not_active Withdrawn
-
2024
- 2024-10-23 CL CL2024003234A patent/CL2024003234A1/es unknown
- 2024-12-03 AU AU2024270619A patent/AU2024270619A1/en active Pending
-
2025
- 2025-06-04 US US19/227,822 patent/US20250296982A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3014619T3 (en) | Optimized fc variants | |
| CN104508133B (zh) | 用于产生单体和多聚体分子的方法及其用途 | |
| US10093714B1 (en) | Method for producing soluble FcR as Fc-fusion with inert immunoglobulin Fc-region and uses thereof | |
| RU2675319C2 (ru) | РАЗРАБОТКА СТАБИЛЬНОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В ДОМЕНЕ Fc | |
| Monnet et al. | Selection of IgG variants with increased FcRn binding using random and directed mutagenesis: impact on effector functions | |
| EP3061770B1 (en) | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects | |
| JP2022120132A (ja) | 操作されたポリペプチドおよびその使用 | |
| CN115667305A (zh) | 修饰的免疫球蛋白fc区 | |
| CN114466663B (zh) | 以FcRn拮抗剂治疗抗体介导的障碍的方法 | |
| US20240043515A1 (en) | Heterodimer fc polypeptide | |
| RU2016139006A (ru) | Мультимерные fc-белки | |
| CN105026430A (zh) | 工程化免疫球蛋白重链-轻链对及其用途 | |
| JP2021500348A (ja) | 単一特異性抗体から多重特異性抗体を生成させるための方法 | |
| CN115135669A (zh) | 修饰的Fc区 | |
| CN121057750A (zh) | 结合ox40l的抗体和使用方法 | |
| AU2015200990A1 (en) | Optimized Fc variants | |
| CN115151567A (zh) | 治疗性Fc组合物的化学诱导结合和解离以及T细胞接合器与人血清白蛋白的化学诱导二聚化 | |
| AU2015202560B2 (en) | Method for Making Antibody Fc-Heterodimeric Molecules Using Electrostatic Steering Effects | |
| RU2810540C2 (ru) | РАЗРАБОТКА СТАБИЛЬНОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В ДОМЕНЕ Fc | |
| Jefferis | Fc Protein Engineering | |
| Jefferis | Antibody Fc: Chapter 17. Fc Protein Engineering | |
| AU2016213792A1 (en) | Optimized Fc variants | |
| HK1197428A (en) | Heterodimerized polypeptide |